Jasper Therapeutics, Inc. (JSPRW)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
Peers in industry
Jasper Therapeutics, Inc. has no peer companies in this window.
Recent press releases
Jasper Therapeutics, Inc. has not issued a press release in this window.
SEC filings
All filings →Jasper Therapeutics, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Jasper Therapeutics, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Jasper Therapeutics, Inc.
All people →No officers or directors have been indexed for Jasper Therapeutics, Inc..